Extravazation of therapeutic yttrium-90-ibritumomab tiuxetan (zevalin): a case report.
The occurrence of radiation necrosis to the extravasation of therapeutic radionuclide-yttrium-90-ibritumomab tiuxetan-is described, as well as the subsequent steps taken to both address the occurrence and to prevent the re-occurrence of such an adverse event. Published reports on the extravasation of diagnostic and therapeutic radionuclides are reviewed, as are prevention and treatment protocols.
Williams
Gethin
G
Nuclear Medicine, Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA 02215-5400, USA.
Palmer
Matthew R
MR
Parker
J Anthony
JA
Joyce
Robin
R
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D005119:Extravasation of Diagnostic and Therapeutic Materials; D006801:Humans; D008297:Male; D008875:Middle Aged; D011832:Radiation Injuries / Q000209:etiology*; D016499:Radioimmunotherapy / Q000009:adverse effects / Q000379:methods; D015021:Yttrium Radioisotopes / Q000009:adverse effects*
D000911:Antibodies, Monoclonal; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan